Drug Profile
Research programme: hepatitis C virus inhibitors - Dong Wha/XTL
Alternative Names: HCV synthetic drug research programme - Dong Wha/XTL; Hepatitis C virus inhibitors research programme - Dong Wha/XTLLatest Information Update: 15 Nov 2002
Price :
$50
*
At a glance
- Originator Dong Wha
- Developer Dong Wha; XTL Biopharmaceuticals
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 15 Nov 2002 Discontinued - Preclinical for Hepatitis C in Israel (unspecified route)
- 15 Nov 2002 Discontinued - Preclinical for Hepatitis C in South Korea (unspecified route)
- 19 Jul 2002 HCV-Trimera disease model is available for licensing (http://www.xtlbio.com)